原发肠道非霍奇金淋巴瘤46例临床特点及治疗分析  

Clinical characteristics and treatment analysis of 46 cases of primary intestinal nonHodgkin lymphoma

作　　者：黄月华[1] 王燕婴 于凡[1] 李硕[1] 王莉莉[2] 

机构地区：[1]清华大学医学中心北京清华长庚医院血液内科,北京102218 [2]山东省烟台市莱阳中心医院血液内科

出　　处：《胃肠病学和肝病学杂志》2016年第2期198-201,共4页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的探讨原发肠道非霍奇金淋巴瘤(primary intestinal non-Hodgkin lymphoma,PI-NHL)的临床特征、影响预后因素及手术治疗对预后的影响。方法对烟台市莱阳中心医院2005年1月-2014年6月收治的46例PI-NHL病历资料进行回顾性分析。结果治疗后随访得到1年总生存率(overall survival,OS)为84.68%,3年OS为73.25%,5年OS为60.82%。手术+化疗及单纯化疗对患者的无进展生存率(progress free survival,PFS)和OS差异均无统计学意义(P>0.05)。B细胞淋巴瘤PFS及OS均好于T细胞淋巴瘤。结论肠道B细胞淋巴瘤生存率高于T细胞淋巴瘤,手术并不能提高PI-NHL患者生存率,且长期生活质量化疗组优于手术组。Objective To analyze the clinical characteristics and nal non-Hodgkin lymphoma （PI-NHL）. Methods The clinical data prognostic factors of patients with primary intesti- of 46 PI-NHL patients admitted from Jan. 2005 to Jun. 2014 were analyzed retrospectively. Results After treatment and follow-up, one-year overall survival （OS）, three-year OS and five-year OS were 84.68% , 73.25% and 60.82% , respectively. Surgery operation could not im- prove PI-NHL patients＇ progress free survival （PFS）. Conclusion It is concluded that surgery can not improve the survival of PI-NHL patients. The quality of life in chemotherapy group is superior than surgery group.

关 键 词：原发肠道非霍奇金淋巴瘤 预后分析 无进展生存时间 总生存时间 

分 类 号：R574.6[医药卫生—消化系统]